Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [ 177Lu-DOTA 0,Tyr 3]octreotate

Journal of Nuclear Medicine

Volumn 52, Issue 9, 2011, Pages 1361-1368

  Khan, Saima ^a   Krenning, Eric P ^a   Van Essen, Martijn ^a   Kam, Boen L ^a   Teunissen, Jaap J ^a   Kwekkeboom, Dik J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

177Lu DOTA 0,Tyr 3 octreotate; Bronchial neuroendocrine tumor; Gastroenteropancreatic neuroendocrine tumor; Health related quality of life; Peptide receptor radionuclide therapy; Quality of life

Indexed keywords

CHROMOGRANIN A; OCTREOTATE LU 177; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; BONE METASTASIS; BRONCHIAL NEUROENDOCRINE TUMOR; BRONCHUS TUMOR; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DYSPNEA; FATIGUE; FEMALE; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NETHERLANDS; NEUROENDOCRINE TUMOR; PAIN; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; TREATMENT OUTCOME; TUMOR REGRESSION;

ANOREXIA; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; EMOTIONS; FEMALE; HEALTH STATUS; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PAIN; PANCREATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; RADIOPHARMACEUTICALS; SOCIAL BEHAVIOR; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 80052612606     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.087932     Document Type: Article

References (40)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
2. Öberg K. Management of neuroendocrine tumours. Ann Oncol. 2004;15(suppl 4):iv293-iv298. (Pubitemid 39585350)
3. Lepage C, Bouvier AM, Phelip JM, Hatem C, Vernet C, Faivre J. Incidence and management of malignant digestive endocrine tumours in a well defined French population. Gut. 2004;53:549-553. (Pubitemid 38372980)
4. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204-2210.
5. Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG. Epidemiology and survival in patients with carcinoid disease in the Netherlands: an epidemiological study with 2391 patients. Ann Oncol. 2001;12:1295-1300. (Pubitemid 32994760)
6. Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C. Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974-97. Br J Cancer. 2000;83:952-955.
7. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
8. Moertel CG. Karnofsky memorial lecture: an odyssey in the land of small tumors. J Clin Oncol. 1987;5:1502-1522.
9. Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol. 2006;24:401-406. (Pubitemid 46630459)
10. Delaunoit T, Rubin J, Neczyporenko F, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol. 2008;103:475-483. (Pubitemid 351248724)
11. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221-232. (Pubitemid 47242624)
12. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897-4904. (Pubitemid 46223995)
13. Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403-3410.
14. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer. 2006;95:1148-1154. (Pubitemid 44660065)
15. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69-76.
16. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311-4318.
17. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
18. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95:3276-3281.
19. Janson ET, Oberg K. Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha interferon. Acta Oncol. 1993;32:225-229. (Pubitemid 23188540)
20. Arnold R, Benning R, Neuhaus C, Rolwage M, Trautmann ME. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group. Digestion. 1993;54:72-75. (Pubitemid 23202566)
21. Ruszniewski P, O'Toole D. Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors. Neuroendocrinology. 2004;80:74-78. (Pubitemid 39382374)
22. Marín C, Robles R, Fernández JA, et al. Role of liver transplantation in the management of unresectable neuroendocrine liver metastases. Transplant Proc. 2007;39:2302-2303. (Pubitemid 47418150)
23. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastroentero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin ana- logue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422. (Pubitemid 36692868)
24. 177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
25. Van Essen M, Krenning EP, Kam BL, De Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol. 2009;5:382-393.
26. Johnson JR, Temple R. Food and Drug Administration requirements for the approval of new anticancer drugs. Cancer Treat Rep. 1985;69:1155-1159.
27. Fröjd C, Larsson G, Lampic C, Von Essen L. Health related quality of life and psychosocial function among patients with carcinoid tumours: a longitudinal, prospective, and comparative study. Health Qual Life Outcomes. 2007;5:18.
28. Davies AH, Larsson G, Ardill J, et al. Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer. 2006;42:477-484. (Pubitemid 43227926)
29. Larsson G, Sjödén PO, Oberg K, Eriksson B, Von Essen L. Health-related quality of life, anxiety and depression in patients with midgut carcinoid tumours. Acta Oncol. 2001;40:825-831. (Pubitemid 34081662)
30. 177Lu-DOTA0,Tyr3] octreotate. J Clin Oncol. 2004;22:2724-2729.
31. Fayers PM, Sprangers MA. Understanding self-rated health. Lancet. 2002;359:187-188. (Pubitemid 34113813)
32. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
33. Fayers PM, Aaronson NK, Bjordal K, Curran D, Groenvold M, on behalf of the EORTC Quality of Life Study Group. The EORTC QLQ-C30 Scoring Manual. 2nd ed. Brussels, Belgium: European Organization for Research and Treatment of Cancer; 1999.
34. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144. (Pubitemid 28041591)
35. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253. (Pubitemid 23008970)
36. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728-734.
37. 18F-FDG PET. J Nucl Med. 2010;51:704-712.
38. Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:459-466.
39. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33:1025-1030. (Pubitemid 27310776)
40. Van Steen K, Curran D, Kramer J, et al. Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med. 2002;21:3865-3868.